|
Back to Home » November 2020 News » Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma |
Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma |
November 24, 2020
OSLO, Norway, Nov. 24, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today releases 18-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with...
Source URL: https://www.prnewswire.com:443/news-releases/targovax-demonstrates-encouraging-survival-data-for-oncos-102-in-mesothelioma-301179436.html
|
|
|
|
